INmune Bio Inc (NASDAQ:INMB) is making progress in regulatory pathways, with positive updates on drug trials and financial management. Challenges include delays in FDA meetings and competition in the gene therapy market. The company is working towards partnerships and addressing Alzheimer's drug development obstacles.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing